BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. Neuropharmacology 2019;151:1-12. [PMID: 30940536 DOI: 10.1016/j.neuropharm.2019.03.033] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, Thakur GA. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorg Med Chem 2021;50:116421. [PMID: 34634617 DOI: 10.1016/j.bmc.2021.116421] [Reference Citation Analysis]
2 Stasiulewicz A, Znajdek K, Grudzień M, Pawiński T, Sulkowska AJI. A Guide to Targeting the Endocannabinoid System in Drug Design. Int J Mol Sci 2020;21:E2778. [PMID: 32316328 DOI: 10.3390/ijms21082778] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
3 Onofrychuk TJ, Cai S, McElroy DL, Roebuck AJ, Greba Q, Garai S, Thakur GA, Laprairie RB, Howland JG. Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task. Prog Neuropsychopharmacol Biol Psychiatry 2021;109:110235. [PMID: 33373679 DOI: 10.1016/j.pnpbp.2020.110235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Mcelroy DL, Roebuck AJ, Greba Q, Garai S, Brandt AL, Yilmaz O, Cain SM, Snutch TP, Thakur GA, Laprairie RB, Howland JG. The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. IBRO Neuroscience Reports 2022. [DOI: 10.1016/j.ibneur.2022.01.006] [Reference Citation Analysis]
5 Leo LM, Abood ME. CB1 Cannabinoid Receptor Signaling and Biased Signaling. Molecules 2021;26:5413. [PMID: 34500853 DOI: 10.3390/molecules26175413] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
6 Schaffer PC, Kulkarni PM, Janero DR, Thakur GA. Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. Bioorg Med Chem 2020;28:115727. [PMID: 33065437 DOI: 10.1016/j.bmc.2020.115727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bruder M, Polo G, Trivella DBB. Natural allosteric modulators and their biological targets: molecular signatures and mechanisms. Nat Prod Rep 2020;37:488-514. [PMID: 32048675 DOI: 10.1039/c9np00064j] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Hurst DP, Garai S, Kulkarni PM, Schaffer PC, Reggio PH, Thakur GA. Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure-Activity Relationship Studies. ACS Med Chem Lett 2019;10:1216-21. [PMID: 31413808 DOI: 10.1021/acsmedchemlett.9b00256] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
9 McElroy DL, Roebuck AJ, Scott GA, Greba Q, Garai S, Denovan-Wright EM, Thakur GA, Laprairie RB, Howland JG. Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies. Psychopharmacology (Berl) 2021;238:1087-98. [PMID: 33442771 DOI: 10.1007/s00213-020-05755-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Manzke P, Crippa JAS, Marchioni C, Queiroz MEC, Brito MCM, Pimentel AV, Bosaipo NB, Foss MP, Tumas V. Circulating Endocannabinoids in Huntington's Disease: An Exploratory Cross-Sectional Study. J Huntingtons Dis 2022;11:91-5. [PMID: 35124656 DOI: 10.3233/JHD-210507] [Reference Citation Analysis]
11 Young AP, Denovan-wright EM. The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation. Front Pharmacol 2022;12:806417. [DOI: 10.3389/fphar.2021.806417] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
12 Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG. Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Front Mol Neurosci 2020;13:54. [PMID: 32410959 DOI: 10.3389/fnmol.2020.00054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
13 Gado F, Mohamed KA, Meini S, Ferrisi R, Bertini S, Digiacomo M, D'Andrea F, Stevenson LA, Laprairie RB, Pertwee RG, Manera C. Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor. Eur J Med Chem 2021;211:113116. [PMID: 33360803 DOI: 10.1016/j.ejmech.2020.113116] [Reference Citation Analysis]
14 Anderson LL, Doohan PT, Hawkins NA, Bahceci D, Garai S, Thakur GA, Kearney JA, Arnold JC. The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome. Neuropharmacology 2021;205:108897. [PMID: 34822817 DOI: 10.1016/j.neuropharm.2021.108897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, Thakur GA. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. J Med Chem 2021;64:8104-26. [PMID: 33826336 DOI: 10.1021/acs.jmedchem.1c00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Joshi N, Onaivi ES. Psychiatric Disorders and Cannabinoid Receptors. Adv Exp Med Biol 2021;1264:131-53. [PMID: 33332008 DOI: 10.1007/978-3-030-57369-0_9] [Reference Citation Analysis]
17 Delorme C, Giron C, Bendetowicz D, Méneret A, Mariani LL, Roze E. Current challenges in the pathophysiology, diagnosis, and treatment of paroxysmal movement disorders. Expert Rev Neurother 2021;21:81-97. [PMID: 33089715 DOI: 10.1080/14737175.2021.1840978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Garai S, Kulkarni PM, Schaffer PC, Leo LM, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, Szczesniak AM, Denovan-Wright EM, Mackie K, Hohmann AG, Reggio PH, Laprairie RB, Thakur GA. Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. J Med Chem 2020;63:542-68. [PMID: 31756109 DOI: 10.1021/acs.jmedchem.9b01142] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
19 Mielnik CA, Lam VM, Ross RA. CB1 allosteric modulators and their therapeutic potential in CNS disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2021;106:110163. [DOI: 10.1016/j.pnpbp.2020.110163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
20 Laprairie RB, Mohamed KA, Zagzoog A, Kelly MEM, Stevenson LA, Pertwee R, Denovan-Wright EM, Thakur GA. Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. Front Mol Neurosci 2019;12:257. [PMID: 31680861 DOI: 10.3389/fnmol.2019.00257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 An D, Peigneur S, Hendrickx LA, Tytgat J. Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products. Int J Mol Sci 2020;21:E5064. [PMID: 32709050 DOI: 10.3390/ijms21145064] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
22 Polini B, Cervetto C, Carpi S, Pelassa S, Gado F, Ferrisi R, Bertini S, Nieri P, Marcoli M, Manera C. Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist. Life (Basel) 2020;10:E333. [PMID: 33302569 DOI: 10.3390/life10120333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zagzoog A, Mohamed KA, Kim HJJ, Kim ED, Frank CS, Black T, Jadhav PD, Holbrook LA, Laprairie RB. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10:20405. [PMID: 33230154 DOI: 10.1038/s41598-020-77175-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
24 Roebuck AJ, Greba Q, Smolyakova AM, Alaverdashvili M, Marks WN, Garai S, Baglot SL, Petrie G, Cain SM, Snutch TP, Thakur GA, Hill MN, Howland JG, Laprairie RB. Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. Neuropharmacology 2021;190:108553. [PMID: 33845076 DOI: 10.1016/j.neuropharm.2021.108553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]